Newdrug designwith covalent modifiers

被引:38
作者
Adeniyi, Adebayo A. [1 ]
Muthusamy, Ramesh [1 ]
Soliman, Mahmoud E. S. [1 ]
机构
[1] Univ KwaZulu Natal, Sch Hlth Sci, ZA-4001 Durban, South Africa
关键词
covalent warheads; docking; high-throughput; rational design; selectivity; CATHEPSIN S INHIBITORS; ACTIVITY-BASED PROBES; DRUG DISCOVERY; KINASE INHIBITORS; IRREVERSIBLE INHIBITORS; ALZHEIMERS-DISEASE; DOCKING; PROTEASE; POTENT; CYSTEINE;
D O I
10.1517/17460441.2016.1115478
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: A major challenge for drug design is the alarming increase in drug resistance, mutations and toxicity. In recent years, covalent drugs have become a promising option to address these problems, due to their significant advantages. These advantages include their ability to target rare, non-conserved residues, shallow binding sites of target proteins and their ability to retain their binding with a receptor for a very long time.Areas covered: This review shows the increasing progress in rational design and virtual screening of covalent drugs and the promising future of accurately predicting effective covalent drugs through in silico screening.Expert opinion: All the current clinically approved covalent drugs were discovered by chance instead of systematic design. There is a promising and commendable effort towards high-throughput screening and the accurate discovery of new covalent inhibitors, which may address the problems of drug resistance and mutation. However, despite the current progression, there is still a need for more rational attention to improve the covalent warhead for improved receptor interaction and selectivity.
引用
收藏
页码:79 / 90
页数:12
相关论文
共 71 条
[1]
Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents [J].
Barak, D ;
Ordentlich, A ;
Kaplan, D ;
Kronman, C ;
Velan, B ;
Shafferman, A .
CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 157 :219-226
[2]
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks [J].
Barf, Tjeerd ;
Kaptein, Allard .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) :6243-6262
[3]
Activity-based protein profiling for the functional annotation of enzymes [J].
Barglow, Katherine T. ;
Cravatt, Benjamin F. .
NATURE METHODS, 2007, 4 (10) :822-827
[4]
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies [J].
Bauer, Renato A. .
DRUG DISCOVERY TODAY, 2015, 20 (09) :1061-1073
[5]
Predicting the Reactivity of Nitrile-Carrying Compounds with Cysteine: A Combined Computational and Experimental Study [J].
Berteotti, Anna ;
Vacondio, Federica ;
Lodola, Alessio ;
Bassi, Michele ;
Silva, Claudia ;
Mor, Marco ;
Cavalli, Andrea .
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (05) :501-505
[6]
Covalent docking using autodock: Two-point attractor and flexible side chain methods [J].
Bianco, Giulia ;
Forli, Stefano ;
Goodsell, David S. ;
Olson, Arthur J. .
PROTEIN SCIENCE, 2016, 25 (01) :295-301
[7]
Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes [J].
Blum, Galia ;
von Degenfeld, Georges ;
Merchant, Milton J. ;
Blau, Helen M. ;
Bogyo, Matthew .
NATURE CHEMICAL BIOLOGY, 2007, 3 (10) :668-677
[8]
Drugs by design [J].
Borman, S .
CHEMICAL & ENGINEERING NEWS, 2005, 83 (48) :28-30
[9]
Bradshaw JM, 2015, NAT CHEM BIOL, V11, P525, DOI [10.1038/nchembio.1817, 10.1038/NCHEMBIO.1817]
[10]
Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors [J].
Cai, Jiaqiang ;
Robinson, John ;
Belshaw, Simone ;
Everett, Kathryn ;
Fradera, Xavier ;
van Zeeland, Mario ;
van Berkom, Leon ;
van Rijnsbergen, Peter ;
Popplestone, Lucy ;
Baugh, Mark ;
Dempster, Maureen ;
Bruin, John ;
Hamilton, William ;
Kinghorn, Emma ;
Westwood, Paul ;
Kerr, Jennifer ;
Rankovic, Zoran ;
Arbuckle, Wullie ;
Bennett, D. Jonathan ;
Jones, Philip S. ;
Long, Clive ;
Martin, Iain ;
Uitdehaag, Joost C. M. ;
Meulemans, Tommi .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (23) :6890-6894